Zim Laboratories Ltd announced its Q4 & FY25 earnings, reporting a total operating income of 3,790 million, a 3.2% increase year-over-year, and a decline in PAT to 122 million due to higher finance costs. The presentation details significant growth in export revenues and new innovative products, alongside a capital expenditure of 365 million and R&D investment of 103 million.